Radiopharm Theranostics reports high success rate in Phase 2b imaging trial

Radiopharm Theranostics (ASX:RAD) has announced encouraging interim results from its U.S.-based Phase 2b clinical imaging trial of RAD 101, reporting that 92 per cent of evaluable patients achieved concordance between RAD 101 PET imaging and MRI, the study’s primary endpoint. …